Home > Insider Trading > Filing (0000947871-23-001148)

Filing Details

Accession Number:: 0000947871-23-001148
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-12-14 17:44:43
Reporting Period:: 2023-12-12

Accepted Time:: 2023-12-14 17:44:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1816736	Disc Medicine Inc.	IRON	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue 54Th Floor New York NY 10022	Yes	No	No	No
1682115	Orbimed Capital Gp Vi Llc	601 Lexington Avenue 54Th Floor New York NY 10022	Yes	No	No	No
1808744	Orbimed Genesis Gp Llc	601 Lexington Avenue 54Th Floor New York NY 10022	Yes	No	No	No
1845804	Orbimed Capital Gp Viii Llc	601 Lexington Avenue 54Th Floor New York NY 10022-4629	Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-12-12	14,400	$60.16	1,182,425	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2023-12-12	9,300	$60.16	764,307	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2023-12-12	3,600	$60.16	295,605	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2023-12-13	56,200	$58.56	1,126,225	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2023-12-13	36,400	$58.56	727,907	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2023-12-13	14,100	$58.56	281,505	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2023-12-14	100	$57.73	1,126,125	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2023-12-14	100	$57.73	727,807	No	4	S	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes

Footnotes

These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.